Study of two medicines for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18–70 and assigned female at birth
- Your cancer has been confirmed as epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
- Your cancer came back within 6 months after your last platinum chemotherapy
- Testing shows an HRR gene mutation in tumor tissue or a blood sample
- You have at least one measurable spot on scans that the study can track
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This trial tests a combination of two drugs, adebrelimab and fuzuloparib, alongside chemotherapy for ovarian cancer that has returned within 6 months of platinum treatment. It aims to see if this combination can help control the cancer better than standard options.
This trial tests a combination of drugs (adebrelimab, chemotherapy, bevacizumab, and fluzoparib) for ovarian cancer that has returned after a period of remission. It may help by using the immune system and targeted therapy to attack cancer cells.
This trial tests a common chemotherapy (Pegylated Liposomal Doxorubicin) plus an immunotherapy (Adebrelimab), with or without a bladder medication (Mirabegron), in people whose ovarian cancer has returned after initial treatment. The goal is to see if adding Mirabegron helps the other drugs work better.
This early-phase study tests a combination of three medicines to treat ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum chemotherapy, especially when tumors have a BRCA1 or BRCA2 mutation. The goal is to see if this treatment can help control cancer that is hard to treat.
This trial tests a new combination of drugs for ovarian cancer that has come back after responding to platinum chemotherapy. The goal is to see if adding these drugs helps control the cancer longer.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.